Financial Performance - For the years ended December 31, 2025 and December 31, 2024, the company incurred net losses of $54.0 million and $56.4 million, respectively, with an accumulated deficit of $521.6 million as of December 31, 2025[176]. - As of December 31, 2025, the company had $69.8 million in cash and cash equivalents and an accumulated deficit of $521.6 million[262]. - The company expects to continue incurring net losses for the next several years and will require substantial additional capital to finance planned operations[261]. - The company may need to raise additional capital through public or private equity offerings or debt financings, which could dilute existing stockholders' ownership[264]. Product and Market Dependence - The company relies heavily on the Zephyr Valve, which is currently approved only for treating severe emphysema, and has no other therapeutic products approved for sale in the United States[179]. - Sales of Zephyr Valves and delivery catheters accounted for most of the company's revenue for the years ended December 31, 2025 and December 31, 2024[180]. - The company derives substantially all revenue from sales to hospitals and distributors, primarily through a direct sales force engaging with pulmonologists[197]. - International sales accounted for approximately 37.0% and 32.6% of revenue for the years ended December 31, 2025, and December 31, 2024, respectively[273]. Regulatory and Compliance Challenges - The company must navigate lengthy and complex purchasing contracts with hospitals to sell the Zephyr Valve, which can delay sales and impact operating results[187]. - Compliance with extensive government regulations is critical; failure to obtain necessary approvals could negatively affect business operations[309]. - The company is under investigation by the U.S. Department of Justice regarding its relationships with healthcare providers, which could lead to increased costs and operational distractions[330]. - The company is required to report any incidents involving its products that may have caused serious injury or death, which could lead to recalls and regulatory scrutiny[324]. Clinical and Safety Concerns - In clinical trials, pneumothoraces occurred in 18-34% of patients treated with the Zephyr Valve, with 17% of these events requiring no intervention[192]. - The long-term effects of the Zephyr Valve treatment are not yet fully understood, with limited long-term data available[208]. - The success of the Zephyr Valve is contingent on adequate physician training, as improper implantation can lead to negative patient outcomes and affect market adoption[188]. - A recall of products due to safety issues could adversely affect the company's reputation and financial performance[323]. Market and Competitive Landscape - The company faces significant competition from established products and companies with greater resources, which may hinder market penetration[254]. - The total addressable market for current and future products may be smaller than estimated, particularly if smoking rates decline, which could reduce the number of patients suffering from COPD and emphysema[240]. - The overall rate of smoking among U.S. adults has declined from 42.4% in 1965 to 11.6% in 2022, which may impact the market for the company's products[240]. Operational Risks - The company faces potential challenges in maintaining physician relationships and compliance with regulatory requirements, which could impact business operations[209]. - The company relies on a limited number of single-source suppliers for critical components, making it vulnerable to supply shortages and price fluctuations[212]. - The company has limited experience in manufacturing products in significant commercial quantities, which may adversely affect its ability to meet customer demand[216]. - The company relies on third-party shipping carriers for timely delivery of its products, and any disruptions could negatively impact operations and reputation[268]. Data Privacy and Cybersecurity - The company launched the LungTraX Platform in 2024, which involves processing patient PHI, posing potential financial and reputational risks[224]. - The company is investing in protections and monitoring practices related to data and IT to reduce risks associated with security incidents[224]. - The company faces challenges in transferring personal data from Europe due to stringent localization laws and potential legal challenges to existing transfer mechanisms[374]. - The GDPR imposes substantial fines for breaches, up to €20 million or 4% of global turnover, whichever is greater, along with potential bans on data processing[373]. Future Growth and Development - The company plans to expand its sales and marketing infrastructure to increase the number of customers and emphysema centers of excellence[207]. - The company is conducting the CONVERT II pivotal trial for the AeriSeal System, aimed at treating severe emphysema patients not qualified for Zephyr Valve treatment[263]. - The company's long-term growth relies on enhancing the Zephyr Valve, Chartis System, and LungTraX Platform, as well as developing new products[293]. - Failure to expand indications and develop new products may impair revenue growth, adversely affecting the company's financial condition[294].

French said the company is streamlining the U.S. sales team’s priorities back to a smaller set of “high-impact mandates” and re-centering activity around what Pulmonx believes historically drove results. As part of organizational changes, French has taken a more direct day-to-day role in the U.S. sales organization, with the two U.S. area vice presidents now reporting directly to him.French said the combination contributed to significant turnover during 2025, estimating turnover at “on the order of half of ...

Management View - Pulmonx Corporation's CEO Glendon French emphasized a strategic bottom-up approach to evaluate the business, focusing on enhancing successful elements and addressing underperforming areas while realigning spending [2] - The company has set a revenue target of $90 million to $92 million for 2026, indicating a clear financial goal as part of its renewed focus on U.S. sales [2] - The management's approach reflects a commitment to operational efficiency and targeted growth strategies in the competitive healthcare market [2]

Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in the same period last year, and a decrease of 7% on a constant currency basis [20] - Worldwide revenue for the full year 2025 was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [20] - U.S. revenue in Q4 was $14.1 million, an 11% decrease from $15.9 million during the same period of the prior year [20] - International revenue in Q4 was $8.5 million, an 8% increase from $7.9 million during the same period last year [22] - Gross margin for Q4 was 77.6%, compared to 74% in the prior year [23] - Net loss for Q4 was $10.4 million or a loss of $0.25 per share, compared to a net loss of $13.2 million or a loss of $0.33 per share for the same period of the prior year [25] - Cash equivalents and marketable securities at the end of 2025 were $69.8 million, a decrease of $31.7 million from December 31, 2024 [26] Business Line Data and Key Metrics Changes - U.S. revenue for the full year 2025 was $57 million, a 1% increase over the prior year [21] - International revenue for the full year 2025 was $33.5 million, an increase of 23% over the prior year [22] - R&D expenses for Q4 were $4.6 million compared to $4 million in Q4 2024, reflecting increased clinical trial activity [24] - Sales, general, and administrative expenses for Q4 were $22.9 million compared to $27 million in Q4 2024 [24] Market Data and Key Metrics Changes - International growth was driven by continued strength in major European markets, offset by a lack of sales to the distributor in China [22] - The distributor in China is working through inventory from large orders placed in the first half of 2025, awaiting the renewal of the Chinese registration certificate expected in the second half of 2026 [22] Company Strategy and Development Direction - The company aims to re-accelerate U.S. sales growth, advance clinical initiatives, and align spending to deliver financial leverage towards profitability [7] - A focus on organizational alignment to optimize resources and decision-making in critical areas has been established [8] - The sales strategy is shifting to prioritize high-impact mandates and streamline the U.S. sales team's focus [10] - The AeriSeal program is a key focus for expanding the market, with the CONVERT II trial expected to complete enrollment in 2027 [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has begun implementing strategies to address these issues [7][8] - The company expects to deliver full-year 2026 revenue in the range of $90 million-$92 million, with a return to year-over-year growth anticipated in the back half of the year [26] - Management is confident in the business fundamentals and is focused on demonstrating meaningful operating leverage and reducing cash burn starting in 2026 [19][28] Other Important Information - A cost restructuring initiative has reduced ongoing operating expenses by over 10% [18] - A $60 million credit facility has been secured, extending the maturity of existing debt to 2031 and providing access to additional capital [18] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [31] Question: How are sales incentives structured now? - The design of the compensation plan has been adjusted to ensure it is reasonable and well-understood, with a focus on effective quota allocation [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline, and new reps require time to ramp up productivity [41] Question: What areas contributed to the 10% cost reduction? - Most savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [46] Question: How will AeriSeal and the CONVERT II trial be balanced with U.S. sales investments? - The company believes that the trial's execution will not significantly impact overall spending and will be aligned with commercial operations [52] Question: What is the status of sales in China? - Sales to China are expected to resume in the back half of 2026, with minimal contributions anticipated in the first half [78]

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAnnie Tripodo - Equity Research AssociateDerrick Sung - COO and CFOGlen French - President and CEOLaine Morgan - Head of Investor RelationsSimran Kaur - Equity Research AssociateConference Call ParticipantsJason Bednar - Managing Director and Senior Research AnalystJon Young - Director and Equity Research AnalystNelson Cox - Equity Research AnalystOperatorThank you for standing by. Welcome to the Pulmonx Q4 2025 ear ...

Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in Q4 2024, and a 7% decrease on a constant currency basis [19] - Full year 2025 revenue was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [19] - U.S. revenue in Q4 2025 was $14.1 million, an 11% decrease from $15.9 million in Q4 2024, while full year U.S. revenue was $57 million, a 1% increase over the prior year [19] - International revenue in Q4 2025 was $8.5 million, an 8% increase from $7.9 million in Q4 2024, and a 2% increase on a constant currency basis [20] - Gross margin for Q4 2025 was 77.6%, up from 74% in the prior year, driven by a lower mix of distributor sales [21] - Net loss for Q4 2025 was $10.4 million, or a loss of $0.25 per share, compared to a net loss of $13.2 million, or a loss of $0.33 per share in Q4 2024 [24] Business Line Data and Key Metrics Changes - The company added 10 new U.S. treating centers during Q4 2025 [19] - R&D expenses for Q4 2025 were $4.6 million, compared to $4 million in Q4 2024, reflecting increased clinical trial activity [23] - Sales, general, and administrative expenses for Q4 2025 were $22.9 million, down from $27 million in Q4 2024 due to cost controls [23] Market Data and Key Metrics Changes - International revenue for the full year 2025 was $33.5 million, a 23% increase over the prior year, and a 19% increase on a constant currency basis [20] - The company expects revenue growth in the first half of 2026 to be negatively impacted by minimal sales to its distributor in China, with a return to growth expected in the second half [25][26] Company Strategy and Development Direction - The company’s top three priorities are re-accelerating U.S. sales growth, advancing clinical initiatives, and aligning spending to achieve profitability [6] - AeriSeal program is a key focus, with expectations to expand the total addressable market by an estimated 20% globally upon completion of the CONVERT II trial in 2027 [14][15] - The company aims to demonstrate meaningful operating leverage and reduce cash burn from $32 million in 2025 to $23 million in 2026, representing a reduction of nearly 30% [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has taken steps to realign the sales organization [6][8] - The company expects U.S. sales growth to resume in the back half of 2026, driven by a refocused commercial strategy and newly filled sales positions [25] - Management remains confident in the business fundamentals and is focused on executing a clear operating plan targeting high-impact initiatives [27] Other Important Information - The company executed a cost restructuring initiative that reduced ongoing operating expenses by over 10% [17] - A $60 million credit facility was closed, extending the maturity of existing debt to 2031 and providing access to additional capital [17] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [29] Question: How are sales incentives structured now? - The company has embraced a new approach to quota allocation and compensation design, ensuring it is reasonable and well-understood by the sales team [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline and needs time for the new sales team to ramp up productivity [40] Question: What changes contributed to the 10% cost reduction? - The majority of the savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [45] Question: How is the AeriSeal trial progressing? - Enrollment in the CONVERT II trial is accelerating, and it is not expected to significantly impact overall company spending [52] Question: What is the outlook for China sales? - Minimal sales are expected in the first half of 2026, with a return to shipments anticipated in the back half of the year [78]

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the f ...

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn CapitalREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors. The credit facility consists of an initial $40 million term loan drawn at closing to refinance th ...

NASDAQ: LUNG March 2026 © 2026 Pulmonx Corporation 1 Forward Looking Statement This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business st ...

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “ ...